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Pathophysiology of Leukocyte-Mediated Tissue Injury 
Peter A. Ward, Gerd 0. Till, and Jeffrey S. Warren 
C ONSIDERABLE new insights have been obtained regarding mechanisms of leuko- 
cyte-mediated tissue injury. Since endothelial 
cell injury often occurs during the acute inflam- 
matory response, much work has been done to 
define in vitro mechanisms involving the killing 
of endothelial cells by activated neutrophils. At 
the same time, the use of in vivo models of acute 
lung injury has allowed definition of events that 
can be linked to the development of acute 
vascular injury by products of activated phago- 
cytic cells. We will briefly review recent studies 
that affect both topics. 
IN VITRO MECHANISMS OF ENDOTHELIAL 
CELL INJURY 
The development of in vitro culture methods 
during the past two decades has permitted a 
detailed analysis of pathways leading to the 
injury of vascular endothelial cells by activated 
neutrophils. Pulmonary vascular endothelial cells 
of bovine, ovine, and rat origin have been 
studied, in addition to cells derived from human 
umbilical vein endothelial cells (HUVECs). Al- 
though there have been some sporadic reports 
using human endothelial cells from other vascu- 
lar beds, most work with human cells has been 
carried out using HUVECs. Our own studies 
have involved the use of rat pulmonary artery 
endothelial cells (RPAECs) to be able to make 
comparisons between the in vitro behavior of 
these cells with their fate in vivo during acute 
inflammatory injury. It must be acknowledged 
that there are differences between endothelial 
cells related to species variations and that within 
a given species there may be considerable differ- 
ences between the behavior of microvascular 
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endothelial cells compared with aortic endothe- 
lial cells. These issues have not been carefully 
resolved because of the inherent difficulties in 
obtaining and maintaining endothelial cell cul- 
ture lines that are of very limited passage in 
culture. 
In the case of RPAECs, there is emerging 
evidence that defines the mechanisms by which 
activated neutrophils bring about damage. “Ad- 
hesive interactions” between neutrophils and 
RPAECs are important in bringing about the 
most efficient contact between these different 
cell types and facilitating the injury of endothe- 
ha1 cells by toxic products of activated neutro- 
phils. Although only studied in a limited man- 
ner, adhesion-promoting molecules on the 
neutrophil include the B2-integrin molecule 
(CD18), while on the endothelial cell, an impor- 
tant adhesion-promoting molecule is endothe- 
lial leukocyte adhesion molecule-l (ELAM-l), 
which is reactive with a member of the selectin 
family of lectin-epidermal growth factor-comple- 
ment regulatory protein cell adhesion mole- 
cules (LEC-CAMS) molecules on the neutro- 
Phil. Other LEC-CAMS include GMP140 and 
MEL-14l.i,, although whether these are impor- 
tant in neutrophil cytotoxic interactions with 
endothelial cells is not currently known.’ 
ELAM-1 binds with a carbohydrate moiety 
recently defined on the neutrophils, namely, 
sialyl-Le”.2~3 The roles of CD18 on the neutro- 
phi1 and of ELAM-1 on the endothelial cell 
infer that at least two distinct and independent 
binding interactions are linked to the cytotoxic 
outcome. 
Another important, recently recognized find- 
ing is that endothelial cells exposed to cytokines 
such as tumor necrosis factor-a or interleu- 
kin-1B demonstrate upregulation of ELAM-1 
and, accordingly, greatly increase adherence 
interactions between neutrophils and endothe- 
ha1 cells.’ A correlate of this is that in such 
cases, endothelial cells that have been pre- 
exposed to either of the two cytokines demon- 
strate greatly increased susceptibility to killing 
by activated neutrophils.4 
The production of toxic oxygen products by 
phorbol ester-stimulated neutrophils is a key 
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feature to the cytotoxic effects on the endothe- 
ha1 cells. Although activated neutrophils gener- 
ate both superoxide anion (O,-) and hydrogen 
peroxide (H202), only the latter seems central to 
killing of endothelial cells since catalase, but 
not superoxide dismutase (which converts O,- 
to H,O,), is protective against neutrophil- 
mediated killing of endothelial cells.5 It also 
appears that myeloperoxidase-induced conver- 
sion of H,O, to hypochlorous acid (HOCI) is not 
required for the in vitro killing of endothelial 
cells by activated neutrophils since chemical 
inactivation of myeloperoxidase does not re- 
duce the cytotoxic effects of activated neutro- 
phils.5 HOC1 may, however, play an important 
role in the injury of the vasculature by neutro- 
phils, since their metalloproteinases (collage- 
nase and gelatinase) can be directly activated by 
contact with HOC1 (reviewed in ref 6). 
H,O, interactions with endothelial cells result 
in an abrupt fall in intracellular levels of adeno- 
sine triphosphate (ATP). Within 20 minutes, 
these levels drop to less than 20% of the normal 
range.7 This fall is due to both reduced synthesis 
of ATP due to inactivation of glyceraldehyde-3- 
phosphate dehydrogenase’ and to a breakdown 
of ATP into adenosind diphosphate, adenosine 
monophosphate, and adenosine, and the subse- 
quent hydrolysis of adenosine (by the action of 
adenosine deaminase) to produce inosine, hy- 
poxanthine, and xanthine.7 The generation of 
the last two metabolites is important for the 
reasons described below. 
lnteraction of RPAECs with activated neutro- 
phils results in an increase in intracellular 
xanthine oxidase.’ This enzyme is known to be 
linked to the presence of its precursor enzyme, 
xanthine dehydrogenase, which can be con- 
verted to xanthine oxidase by a reversible oxida- 
tive change or by an irreversible change that 
may be related to limited proteolysis of xanthine 
dehydrogenase.‘” The “converting factor” from 
the neutrophil appears not to be a product of 
oxygen but, rather, seems to be due to elastase, 
a potent enzyme secreted from cytoplasmic 
granules of the neutrophil.” The increase in 
xanthine oxidase within the endothelial cell as 
well as the appearance of its substrates in cells 
exposed to H,O, sets the stage for the intracellu- 
lar generation of O,-. At present, it can be 
argued that observations dealing with rat endo- 
thelial cell may not be extrapolatable to HU- 
VECs, since the latter do not contain measur- 
able xanthine oxidase. On the other hand, 
subjecting HUVECs to anoxic conditions fol- 
lowed by reoxygenation has been reported to 
result in the appearance of xanthine oxidase 
activity, based on immunohistochemical and 
biochemical analyses.‘* Recently, it also has 
been shown that venous outflow in the extremi- 
ties of humans subjected to ischemia-reperfu- 
sion events results in the appearance of effluent 
plasma of xanthine oxidase.13 Thus, xanthine 
oxidase may exist in human endothelial cells in 
a cryptic or unexpressed form. It seems undeni- 
ably clear that damage to or killing of endothe- 
lial cells is the ultimate result of the formation 
of the highly reactive hydroxyl radical (HO.), 
whose most relevant target in the endothelial 
cell is not clear. HO. is generated by one of two 
known pathways: 
1. The iron-catalyzed Haber-Weiss reaction: 
O,- + Fe3+ + 0, + Fe” 
Fe’+ + H,O, -+ HO* + HO- + Fe”+ 
2. The peroxynitrate pathway: 
O,- + *NO (nitric oxide) + ONOO- 
(peroxynitrite anion) 
ONOO- + H’ = ONOOH 
ONOOH * HO. 
+ *NO, (nitrogen dioxide) 
u 
N03- (nitrate anion) 
It is not clear which of these reactions predom- 
inates in the cytotoxic actions of neutrophils on 
endothelial cells; the evidence is conflicting. On 
the one hand, the presence of the iron chelator, 
deferoxamine, which interacts with Fe3+ in the 
endothelial cells, is highly protective against 
neutrophil-mediated cytotoxicity,5,‘4 and addi- 
tion of iron to endothelial cells causes them to 
be highly susceptible to neutrophil-mediated 
injury. On the other hand, it has been shown 
that deferoxamine will react with peroxynitrite 
to block the formation of HO..” While neutro- 
phils generate very small amounts of .NO, 
macrophages stimulated with endotoxin and 
endothelial cells stimulated with bradykinin or 
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acetyl choline produce much larger amounts of 
.NO. In fact, *NO is the endothelial-derived 
relaxing factor, which appears to regulate vascu- 
lar tone. It will be important to define the extent 
to which either or both of the pathways listed 
above contribute in vitro and in vivo to endothe- 
ha1 cell killing by products of activated neutro- 
phils. 
IN WV0 MECHANISMS OF ACUTE VASCULAR 
INJURY 
Lung Injury Following Systemic Activation of 
Complement 
Two models of acute pulmonary vascular 
injury in rats have been highly instructive. In 
one, acute vascular injury is produced by the 
bolus intravenous infusion of cobra venom fac- 
tor (CVF), which is a highly potent activator of 
the alternative complement pathway, resulting 
in the generation of anaphylatoxins, C3a and 
C5a, and the membrane attack complex, C5b-9. 
This abrupt intravascular activation of comple- 
ment results in the activation and aggregation of 
blood neutrophils that became entrapped within 
the pulmonary microvasculature, bringing about 
the focal damage and destruction of endothelial 
cells, with resulting intra-alveolar edema, fibrin 
deposition, and hemorrhage.lh This model may 
be a prototype of human adult respiratory 
distress syndrome and has accordingly been 
studied in some detail. The damage of vascular 
endothelial cells is neutrophil and complement 
dependent, since lack of access to either pro- 
foundly reduces the expression of vascular dam- 
age. Endothelial cell injury is also dependent on 
the formation of toxic oxygen products of the 
neutrophil (catalase is highly protective), with 
HO* being the ultimate tissue-damaging spe- 
cies.” While the iron chelator, deferoxamine, is 
highly protective against lung injury in the CVF 
model of lung injury, for the reasons outlined 
above, the pathway from which HO. (which 
appears to be the critical tissue-damaging fac- 
tor) occurs cannot be clearly discerned. 
While complement or neutrophil depletion is 
highly protective against lung injury, as is the 
infusion of catalase or scavengers of HO* (di- 
methyl thiourea, dimethyl sulfoxide), additional 
new insights into the pathways leading to injury 
have been obtained. The treatment of rats with 
cromolyn (which has as one of its effects the 
inhibition of histamine release from mast cells 
and basophils) results in an 84% reduction in 
lung injury. In addition, the use of the two 
xanthine oxidase inhibitors, allopurinol and lo- 
doxamine, has also diminished lung injury by 
51% to 63%.18 Although these observations may 
superficially seem disparate, they may be linked 
to our recent reports that histamine can interact 
with xanthine oxidase to cause an increase in its 
catalytic activity.” Accordingly, the scheme of 
events (Fig 1) leading to acute vascular injury in 
the pulmonary microvasculature following sys- 
temic activation results in anaphylatoxin gener- 
ation, with C5a putatively causing histamine 
release and C5a causing direct activation of 
intravascular neutrophils. The presence of hista- 
mine may enhance the catalytic activity of xan- 
thine oxidase within endothelial cells, while, as 
described above, activated neutrophils may also 
secrete elastase which, if it gains entry into the 
vascular endothelial cells, can also increase the 
amount of xanthine oxidase within endothelial 
cells. It would then appear that release of H,O, 
from neutrophils results in the breakdown of 
ATP in the pulmonary vascular endothelial cells 
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Fig 1. Acute microvascular injury in lung following intravas- 
cular activation of complement. 
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thine oxidase, namely, hypoxanthine and xan- 
thine. This production of O,- by the endothelial 
cell may be critical to the formation of HO., 
whether HO. is generated by the Haber-Weiss 
reaction or by the peroxynitrite reaction (as 
described above). Because of differences in 
xanthine oxidase levels in endothelial cells, 
plasma, and tissues in various species, one must 
be cautious in extrapolating the scheme shown 
in Fig 1 to human pathophysiology. However, it 
does seem appropriate to consider that similar 
pathways may be operative in humans. 
Lung Injury Following Intra-alveolar Deposition 
of Immune Complexes 
A second model of acute lung injury has been 
developed in rats by the intra-alveolar deposi- 
tion of immune complexes.” Either intact, pre- 
formed immunoglobulin G-containing immune 
complexes can be instilled intratracheally or 
antibody (anti-bovine serum albumin) can be 
similarly instilled while antigen (bovine serum 
albumin) is injected intravenously. Acute hem- 
orrhagic alveolitis ensues within a 3- to 4-hour 
period. This is a highly reproducible model of 
acute lung injury and, although the relevance of 
this model to human disease can be argued, the 
experimental model has nevertheless lent itself 
to a careful definition of pathophysiologic events 
leading to acute lung injury. This model of lung 
injury is, like the CVF model, dependent on the 
availability of both complement and neutro- 
phils. In this model, there is an intense intra- 
alveolar accumulation of neutrophils. There is 
also compelling evidence that in contrast to the 
CVF model of lung injury, immune complex- 
induced injury is not only the result of products 
released from activated neutrophils but also of 
products released from lung macrophages. The 
proposed outline of events is shown in Fig 2. 
Intra-alveolar deposition of immune complexes 
leads to complement activation and to activa- 
tion of alveolar macrophages.2’*22 The latter cells 
release at least three important products: oxy- 
gen derivatives (O,- and H,O,), platelet-activat- 
ing factor (PAF), and cytokines (tumor necrosis 
factor-a and interleukin-16). Tumor necrosis 
factor-a, which is present in high concentrations 
in the bronchoalveolar lavage fluids of animals 
undergoing interpulmonary deposition of im- 
mune complexes, seems to be essential for the 
intraalveolar deposition of immune complexes 
complement and macrophage activation 
4 4 + 4 
C5a TNFa PAF H202, 05 
c 
upregulation of 






Fig 2. Acute lung injury following deposition of immunoglo- 
bulin G immune complexes. 
recruitment of neutrophils. It seems likely that 
this may be due to the upregulation on endothe- 
lial cells of adhesion-promoting molecules, such 
as ELAM-1 (see above). Expression of ELAM-1 
seems to be required for the intra-alveolar 
accumulation of neutrophils. The lipid factor 
(PAF) produced by alveolar macrophages also 
plays an important role in the outcome of injury, 
since interception of its action by the presence 
of antagonists of PAF receptors greatly reduced 
intrapulmonary injury after deposition of im- 
mune complexes.‘* Platelet-activating factor re- 
ceptor antagonists do not interfere with the 
recruitment of neutrophils. They seem to block 
the effects of PAF on recruited neutrophils, 
including “priming” these cells for enhanced 
responses or the direct stimulation of neutro- 
phils. Ultimately, damage of vascular endothe- 
lia cells and alveolar epithelial cells is due to the 
release of the oxidants from neutrophils and, 
perhaps, also from macrophages. The chief 
oxidant incriminated in the injury is, again, 
HO.. 
What is interesting in the comparison of these 
two models of acute lung injury is the evidence 
that in one (immune complex-induced injury), 
products of macrophages, including cytokines, 
play a prominent role, whereas in the other, 
cytokines do not appear to play an important 
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role (eg, infusion of antibody to block tumor 
necrosis factor-a does not reduce pulmonary 
injury in the CVF model). The complexity of 
events that result in damage of endothelial cells 
(and other cell types) either in vitro or in vivo 
seems somewhat daunting, and the recognition 
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of the diversity of pathways of injury paves the 
way for the consideration of a variety of thera- 
peutic interventions that, in human inflamma- 
tory diseases, should yield beneficial clinical 
outcomes. 
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